Neurocrine Biosciences CFO Matt Abernethy received 5,020 shares at $0 on September 11, then forfeited 2,709 shares and sold 2,311 shares, leaving 42,808 shares after the sale. The sequence gives investors the reported award, withholding-related transaction and sale details tied to his holdings.
Key Highlights
- Matt Abernethy forfeited 2,709 Neurocrine Biosciences shares at $156.22 per share on September 11.
- The CFO sold 2,311 shares at $157.20 per share on September 14.
- Abernethy held 42,808 Neurocrine Biosciences shares after the sale.
Neurocrine Biosciences Inc (NASDAQ: NBIX) awarded Chief Financial Officer Matt Abernethy 5,020 shares at $0 on September 11. The award was followed by a share forfeiture and a sale recorded in separate transactions.
CFO Share Transactions on September 11 and September 14
The September 11 forfeiture involved 2,709 shares at $156.22 per share. Abernethy held 45,119 shares after that transaction, equal to about 5.7% of his prior holding. On September 14, he sold 2,311 Neurocrine Biosciences shares at $157.20 per share and held 42,808 shares afterward, representing about 5.1% of his prior holding.
Transaction Codes and Reported Holdings
After the award, Abernethy’s reported holding was 47,828 shares, and the award represented about 10.5% of that resulting position.
FAQs
Q: How many Neurocrine Biosciences shares did Matt Abernethy receive?
A: Neurocrine Biosciences CFO Matt Abernethy received 5,020 shares at $0 on September 11. The award was recorded under transaction code A.
Q: How many shares did the Neurocrine CFO sell?
A: Matt Abernethy sold 2,311 Neurocrine Biosciences shares at $157.20 per share on September 14. His reported holding afterward was 42,808 shares.
Q: What happened to Abernethy’s shares after the award?
A: Abernethy’s holding was reported at 47,828 shares after the award. He later forfeited 2,709 shares at $156.22 per share and sold 2,311 shares at $157.20 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.